BELLINDA is a trade name and the chemical name is Tegretol. Its main efficacy and effects: It is indicated for patients with acute coronary syndromes, including unstable angina, non-ST elevation myocardial infarction and ST elevation myocardial infarction, and also for patients receiving pharmacological therapy and percutaneous coronary intervention, and is effective in reducing the incidence of thrombotic cardiac and cerebral events. This drug is an anti-platelet aggregation agent that has been marketed in recent years and is able to reduce the incidence of the composite endpoint of cardiovascular death, myocardial infarction and stroke compared to the traditional anti-platelet aggregation drug clopidogrel. The differences between the two treatments stemmed mainly from cardiovascular and myocardial infarction, while there were no differences in the aspect of stroke. The dose of Tegretol is typically 90 mg twice a day and can be taken before or after a meal. Common adverse reactions during administration may include hyperuricemia, various types of bleeding including cerebral hemorrhage, intracranial hemorrhage, and in some patients, respiratory distress. However, in general, it is safe and well tolerated by most patients while taking it. If you experience any discomfort, please visit a specialist as soon as possible.